Trial summary: a randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection
Site and lead:
- Wythenshawe Hospital, Dr Tim Felton
Patient group: All COVID-19 patients
Funder: Synairgen Research Limited
Sponsor: Synairgen Research Limited
More about the Synairgen SNG001 study
- Synairgen SNG001 is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website
- Read more about the Synairgen SNG001 study at MFT via our website news story.
The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of lower respiratory tract (LRT) illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.
SNG001 is an inhaled formulation of interferon-beta-1a (IFN-β1a), a respiratory drug which has been found to inhibit viruses and boost antiviral responses in the lungs. It has already been used in clinical trials of patients with asthma and COPD. These earlier trials indicated that SNG001 was well tolerated during virus infections and provided significant lung function benefit for asthma patients, compared to a placebo.